by Oncololgy News Central
Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types. 333719
Language
🇺🇲
Publishing Since
10/3/2018
Email Addresses
1 available
Phone Numbers
0 available
April 17, 2025
<p>When it comes to tackling fertility issues associated with cancer, “oncology clinicians are often reluctant to talk about this because it is really not our wheelhouse,” says <span lang="EN" xml:lang="EN"><a href= "https://www.pennmedicine.org/providers/profile/alison-loren"><span lang="EN-US" xml:lang="EN-US">Alison Wakoff Loren, MD, MSCE</span></a></span>, chief of the Division of Hematology Oncology, director of Blood and Bone Marrow Transplantation, and the C. Willard Robinson Professor of Hematology-Oncology at Penn Medicine in Philadelphia. Dr. Loren and colleagues recently <span lang="EN" xml:lang="EN"><a href= "https://ascopubs.org/doi/10.1200/JCO-24-02782"><span lang="EN-US" xml:lang="EN-US">updated American Society of Clinical Oncology guidelines</span></a></span> for fertility preservation in people with cancer. She discusses the key changes with Robert Figlin, MD, interim director at Cedars Sinai Cancer Center in Los Angeles and the Steven Spielberg Family Chair in Hematology-Oncology. “This is a really important topic that I think sometimes gets lost in the shuffle of the hecticness of a young person’s cancer diagnosis,” Dr. Loren explains. Increased awareness among oncologists is a crucial step that can lead to faster referrals and interventions, she says. “You better be ready for the conversation,” she urges.</p> <p class="MsoNormal">Dr. Loren reported research funding from Equillium (Inst).</p> <p class="MsoNormal">Dr. Figlin reported <span lang="EN" xml:lang="EN"><a href= "https://www.oncologynewscentral.com/contributor/robert-a-figlin-md-facp"> <span lang="EN-US" xml:lang="EN-US">various financial relationships</span></a></span>.</p>
April 15, 2025
<p>“Second-line [estrogen receptor (ER)]-positive breast cancer has just become very complicated,” says <a href= "https://sarahcannon.com/physicians/profile/Dr-Erika-P-Hamilton-MD" target="_blank" rel="noopener">Erika P. Hamilton, MD</a>, the director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville. She discusses the role of ESR1 mutations in selecting appropriate treatments and combination regimens for patients with ER-positive breast cancer who have disease progression with <span lang="EN" xml:lang="EN"><a href= "https://www.cedars-sinai.org/provider/robert-figlin-1071249.html"><span lang="EN-US" xml:lang="EN-US">Robert A. Figlin, MD</span></a></span>, the interim director of Cedars-Sinai Cancer in Los Angeles, and Steven Spielberg Family Chair in Hematology-Oncology. From when and how best to assess for ESR1 mutations to which trials inform current treatment options in clinic, Dr. Hamilton walks through the complex decision-making process. She also shares which trial readouts she is looking forward to seeing and how social media is influencing patient choices.</p> <p class="MsoNormal">Dr. Hamilton reported <span lang="EN" xml:lang="EN"><a href= "https://www.oncologynewscentral.com/contributor/erika-hamilton-md"> <span lang="EN-US" xml:lang="EN-US">various financial relationships</span></a></span>.</p> <p class="MsoNormal">Dr. Figlin reported <span lang="EN" xml:lang="EN"><a href= "https://www.oncologynewscentral.com/contributor/robert-a-figlin-md-facp"> <span lang="EN-US" xml:lang="EN-US">various financial relationships</span></a></span>.</p>
April 7, 2025
<p class="MsoNormal">Burnout among oncologists is a <span lang="EN" xml:lang="EN"><a href= "https://www.oncologynewscentral.com/podcast/oncology/asco-president-speaks-out-on-huge-problem-of-oncologist-burnout"><span lang="EN-US" xml:lang="EN-US">serious concern</span></a></span>, and artificial intelligence (AI) represents a potential solution, says <span lang= "EN" xml:lang="EN"><a href= "https://www.texasoncology.com/oncologist/debra-patt"><span lang= "EN-US" xml:lang="EN-US">Debra Patt, MD, PhD, MBA</span></a></span>, a practicing oncologist and breast cancer specialist in Austin, Texas, who also serves as the chair of the AI task force for the American Society of Clinical Oncology. Technological advances are poised to improve cancer care while reducing the documentation burden for oncologists, she tells <span lang="EN" xml:lang="EN"><a href= "https://www.cedars-sinai.org/provider/robert-figlin-1071249.html"><span lang="EN-US" xml:lang="EN-US">Robert A. Figlin, MD</span></a></span>, the interim director of Cedars-Sinai Cancer in Los Angeles, and Steven Spielberg Family Chair in Hematology-Oncology. Dr. Patt describes the various practical ways in which AI is already changing oncology clinics, but acknowledges a generational divide that will need to be bridged: “I would say that the youngest generation of oncologists that is coming out, they are digital natives. They have grown up with this,” she explains. But for those who have been in practice longer, “Change management for us looks a little bit different than it does for the younger generation of oncologists that just sort of do this naturally.”</p> <p class="MsoNormal">Dr. Patt reported no relevant financial disclosures.</p> <p class="MsoNormal">Dr. Figlin reported <span lang="EN" xml:lang="EN"><a href= "https://www.obroncology.com/contributor/robert-a-figlin-md-facp"> <span lang="EN-US" xml:lang="EN-US">various financial relationships</span></a></span>.</p>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.